The Effect of High-Volume Walking With Visual Cues (VC) in Parkinson´s Disease (PD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

People with disease (PD) tend to walk with short steps, decreased velocity, and increased stride time variability. Short steps and increased variability are related to greater fall risk. In addition, concurrent performance of a cognitive task (dual-task (DT)) has marked effects on gait in people with PD which is considered to reflect an impaired automaticity of gait.

Objective: To investigate short and long term effects of high-volume walking with visual spatial cues (VSC) on gait variables, automaticity, and functional mobility, in people with Parkinson´s Disease (PD), compared with walking without VSC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Attentional Focus Strategy on Dual-task Walking Training in Patients With Parkinson's Disease

NCT04364152

Parkinson Disease Dual-task Walking

COMPLETED NA

Wearable Visual Cues in Parkinson's Disease

NCT05478187

Parkinson Disease Movement Disorders Gait Disorders, Neurologic

COMPLETED NA

Gait Disorders in Parkinson's Disease

NCT03416452

Parkinson's Disease

WITHDRAWN EARLY_PHASE1

The Effects of 24-Weeks Community-based Brisk Walking in People With Parkinson's Disease

NCT06707402

Parkinson Disease

RECRUITING NA

Comparison of Sensory Cuing Modalities for Freezing of Gait

NCT05080413

Parkinson Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson´s Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Walking with visual cues

Walking with visual cues for 30 minutes, 4 times a week for 4 weeks

Group Type EXPERIMENTAL

Visual Cues

Intervention Type OTHER

Walking with visual cues for 30 minutes, 4 times a week for 4 weeks

Walking without visual cues

Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4 times a week for 4 weeks.

Group Type ACTIVE_COMPARATOR

Walking without visual cues

Intervention Type OTHER

Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Visual Cues

Walking with visual cues for 30 minutes, 4 times a week for 4 weeks

Intervention Type OTHER

Walking without visual cues

Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* a confirmed diagnosis of PD according to the UK Parkinson´s Disease Society Brain Bank Clinical Diagnostic Criteria (18)
* \<80 years of age
* community residing
* Hoehn and Yahr (HY) stage 2-3
* Mini Mental State Examination (MMSE) score of \>23
* ability to walk without walking aids for a total of 20 minutes over a 30-minute period

Exclusion Criteria

* major modifications of Parkinson´s medication (Madopar \>200 mg/d or \>20% increase in Dopamine agonists) 3 weeks prior to baseline assessment
* comorbidities or disabilities, which might influence walking
* a history of brain surgery

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No